Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Phase 1

Terminated

Conditions: Solid Tumors and Lymphomas

Interventions: Drug: MIW815
Biological: PDR001

First Posted Date: 2017-06-01

Last Posted Date: 2022-05-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 106

Registration Number: NCT03172936

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇨🇭
Novartis Investigative Site, Zurich, Switzerland

and more 1 locations

Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

Phase 2

Completed

Conditions: Acute Uncomplicated Plasmodium Falciparum Malaria

Interventions: Drug: KAF156
Drug: Coartem
Drug: Lumefantrine Solid Dispersion Formulation

First Posted Date: 2017-05-25

Last Posted Date: 2022-02-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 524

Registration Number: NCT03167242

Locations: 🇻🇳
Novartis Investigative Site, Binh Phuoc Province, VNM, Vietnam

Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Salmeterol/fluticasone plus tiotropium
Drug: QVM149

First Posted Date: 2017-05-18

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1426

Registration Number: NCT03158311

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Phase 2

Terminated

Conditions: Diabetes Mellitus and Heart Failure

Interventions: Drug: LIK066
Drug: Empagliflozin
Drug: Placebo

First Posted Date: 2017-05-15

Last Posted Date: 2019-08-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 125

Registration Number: NCT03152552

Locations: 🇬🇧
Novartis Investigative Site, Birmingham, United Kingdom

Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome

Phase 2

Completed

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: LIK066
Drug: Placebo

First Posted Date: 2017-05-15

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 29

Registration Number: NCT03152591

Locations: 🇩🇪
Novartis Investigative Site, Freiburg, Germany

Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

Phase 4

Completed

Conditions: Glaucoma

Interventions: Drug: brinzolamide 1%/brimonidine 0.2% fixed combination
Drug: Placebo
Drug: travoprost 0.004% ophthalmic solution

First Posted Date: 2017-05-12

Last Posted Date: 2019-02-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1

Registration Number: NCT03150160

Locations: 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of

A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder

Phase 2

Terminated

Conditions: Circadian Rhythm Disorders

Interventions: Drug: LML134
Drug: Placebo

First Posted Date: 2017-05-04

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT03141086

Locations: 🇺🇸
Novartis Investigative Site, Cincinnati, Ohio, United States

Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: NVA237 (glycopyrronium bromide)
Drug: Placebo

First Posted Date: 2017-05-03

Last Posted Date: 2019-01-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 148

Registration Number: NCT03137784

Locations: 🇱🇹
Novartis Investigative Site, Klaipeda, Lithuania

A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: CSJ117
Drug: Placebo Comparator

First Posted Date: 2017-05-03

Last Posted Date: 2021-10-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT03138811

Locations: 🇩🇪
Novartis Investigative Site, Mainz, Germany

SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis

Phase 3

Completed

Conditions: Spondyloarthritis

Interventions: Biological: AIN457
Drug: AIN457 Placebo

First Posted Date: 2017-05-02

Last Posted Date: 2021-09-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 383

Registration Number: NCT03136861

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy